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Although deep brain electrical stimulation can alle-
viate the motor symptoms of Parkinson disease
(PD), just a small fraction of patients with PD can
take advantage of this procedure due to its invasive
nature. A significantly less invasivemethod—epidural
spinal cord stimulation (SCS)—has been suggested
as an alternative approach for symptomatic treat-
ment of PD. However, the mechanisms underlying
motor improvements through SCS are unknown.
Here, we show that SCS reproducibly alleviates mo-
tor deficits in a primate model of PD. Simultaneous
neuronal recordings from multiple structures of the
cortico-basal ganglia-thalamic loop in parkinsonian
monkeys revealed abnormal highly synchronized
neuronal activity within each of these structures and
excessive functional coupling among them. SCS dis-
rupted this pathological circuit behavior in a manner
that mimics the effects caused by pharmacological
dopamine replacement therapy or deep brain stimu-
lation. These results suggest that SCS should be
considered as an additional treatment option for
patients with PD.
INTRODUCTION
Chronic electrical stimulation of subcortical brain structures, a
procedure known as deep-brain stimulation (DBS), has become
an important complement to dopamine replacement therapy in
the symptomatic treatment of Parkinson disease (PD) (Benabid
et al., 1987). However, partially because of the highly invasive
nature of this surgical procedure (Morgante et al., 2007) and its716 Neuron 84, 716–722, November 19, 2014 ª2014 Elsevier Inc.need for additional complex and costly technologies, only a small
fraction of all patients with PD who could possibly benefit from
this therapy are actually eligible for implantation. In this context,
the recent demonstration that electrical epidural spinal cord stim-
ulation (SCS) alleviates akinesia in rodent models of PD (Fuentes
et al., 2009) and reduces motor symptoms in patients (Agari and
Date, 2012; Fe´nelon et al., 2012; Hassan et al., 2013; Landi et al.,
2012) is a significant finding because SCS, unlike DBS, is mini-
mally invasive. Following the initial report on rodent PD models,
SCS has been evaluated for treatment of PD in a few clinical
case studies. Results of these studies range from nomeasurable
improvements in two patients (Thevathasan et al., 2010) to signif-
icant symptomatic relief (Agari and Date, 2012; Fe´nelon et al.,
2012; Hassan et al., 2013; Landi et al., 2012) in 19 patients.
More importantly, in some cases SCS achieved PD symptom
relief equivalent to the best effects obtained with pharmacolog-
ical treatment (Fe´nelon et al., 2012). At present, the underlying
causes for the different outcomes in these preliminary clinical
studies are not known, but variations in electrode design, spinal
cord implantation location, and choice of stimulation parameters
have been suggested as possible contributing factors (Fuentes
et al., 2010; Nicolelis et al., 2010). One way to optimize the
application of this potential therapy for PD is to establish what
neurophysiological changes are associated with the relief of
symptoms, and to evaluate how these changes can be most
effectively induced. Here, we have addressed these questions
by characterizing the behavioral and neurophysiologic SCS
effects in 6-OHDA (6-hydroxydopamine) lesioned marmoset
monkeys (Callithrix jacchus), a primate model of PD.
RESULTS
Using previously described procedures (Annett et al., 1992;
Mitchell et al., 1995), five adult male marmosets were caused
to be parkinsonian through 6-OHDA stereotacticmicro-injections
in the medial forebrain bundle of either one (n = 2) or both
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Spinal Cord Stimulation Alleviates Parkinsonismhemispheres (n = 3). Injections resulted in neurodegeneration of
the midbrain dopaminergic neurons projecting to the forebrain
in the lesioned hemispheres, as assessed postmortem through
immunohistochemical quantification of tyrosine hydroxylase (Fig-
ure S1 available online). In lesioned animals, the number of dopa-
minergic neurons in the midbrain was reduced to 42% ± 23% of
the values observed in control animals. In addition, axonal termi-
nal staining density in the caudate-putamen decreased to 44%±
10% of the levels seen in normal subjects. The severity of parkin-
sonism was regularly examined in all marmosets using manual
scoring of a wide range of clinical signs/deficits (see Supple-
mental Experimental Procedures and Movie S1 for details) and
automated quantification of spontaneous motor behavior. On
average, spontaneous locomotionwas reduced to approximately
one-fourth of prelesion activity, and PD signs approached the
maximum score (mean ± SD: 75% ± 29%) in all the eight cate-
gories assessed (Bankiewicz et al., 2001; Verhave et al., 2009).
Once PD clinical signs had been confirmed, animals under-
went implantation with bipolar epidural SCS electrodes posi-
tioned symmetrically over the dorsal midline of the spinal cord
at a high thoracic level (T3–T4). Four of the five animals (two
with bilateral and two with unilateral medial forebrain bundle le-
sions) also underwent chronic implantation with microelectrode
arrays/bundles in both hemispheres for subsequent recording
of neuronal ensemble activity (both single units and local field
potentials [LFPs]; Figure S2). These implants targeted multiple
structures in each animal, including the primary motor cortex,
putamen, the subthalamic nucleus, globus pallidus pars externa
(GPe) and interna, and the ventrolateral and ventral posterolat-
eral thalamic nuclei. In the two unilateral lesion animals, instead
of the globus pallidus, parts of primary somatosensory cortex
were implanted. Prior to SCS, all animals were also subjected
to acute pharmacological inhibition of dopamine synthesis (sub-
cutaneous injections of alpha-methyl-p-tyrosine [AMPT] 2 3
240 mg/kg) to further aggravate the PD signs.
To avoid SCS current intensities that could be experienced as
uncomfortable, before each stimulation session the intensity of
each stimulation frequency was adjusted and set to 1.7 times
the minimum intensity at which any behavioral response could
be consistently detected (small postural changes, head or neck
movements). Overall, as previously reported in rodents (Fuentes
et al., 2009), we observed that SCS induced a clear alleviation
of motor impairment in monkeys who exhibited severe clinical
PD signs. Because the stimulation frequencies used in this study
(range, 4–300 Hz) proved equally effective, the analysis of the
SCS effects, both behavioral and electrophysiological, were
performed by pooling all the frequencies, unless otherwise
stated. All recordings/stimulation sessions were performed in
freely behaving animals in a transparent acrylic box. Based on
our automated image analysis of digital videos obtained from
multiple cameras during neuronal recording sessions, SCS
induced a 221% increase in general motility of trunk, head, limbs,
and tail (p < 0.05, Wilcoxon signed rank test, Figure 1A), a 192%
increase in the frequency of bouts of spontaneous locomotion
(p < 0.001, two-proportional z test, Figure 1B), and a 144% in-
crease in the duration of locomotion periods (p < 0.05, Wilcoxon
rank sum test, Figure 1C). These improvements resulted in a
243% increase in the total distance covered (p < 0.05, Wilcoxonrank sum test, Figure 1D) by the monkeys. Remarkably, SCS
induced a preferential increase in the fraction of faster locomotion
components, indicating a specific reduction of bradykinesia, (p <
0.05, Kolmogorov-Smirnov test of difference in speed histogram
distributions, Figure 1E). Overall, the resulting distance covered in
locomotive behavior was practically normalized by SCS (on
average 91% of intact values, but locomotion differed somewhat
in that stimulated animals tended to extend bout duration [628%]
whereas reducing the frequency [11%] compared to the intact
state). The improvements in motor disability were also assessed
by an observer blinded to stimulation conditions that rated spe-
cific clinical signs, such as freezing, hypokinesia, bradykinesia,
coordination, gait, posture, and gross and finemotor skills, during
the OFF and ON periods. The motor deficits that exhibited the
highest reduction during SCS were freezing (31%), hypokinesia
(23%), posture (23%), and bradykinesia (21%). Overall, the PD
score showed, on average, a significant reduction of 18.4% ±
13.9% (p < 0.001, Wilcoxon signed rank sum test [including all
five subjects], Figure 1F; Figure S1).
In addition to the general clinical improvements observed in all
monkeys, in a few instances SCS resulted in an extraordinary
functional recovery. An example of this is shown in Figure 1G,
where a severely parkinsonian animal, who reached the
maximumPD score on all clinical signs rated, showed a dramatic
improvement during SCS. This allowed the animal to find and
retrieve a food item with no difficulty whatsoever (see Movie S2).
Chronic, multisite neuronal extracellular activity was analyzed
both in terms of changes in single neuron’s firing patterns and at
the level of LFPs. We observed that SCS induced changes in
neural populations throughout the cortico-basal ganglia-
thalamic loop in parkinsonian animals (Figure 2A). As shown in
Figures 2B and 2C, the most noticeable effect was the suppres-
sion of LFP power in a frequency interval roughly spanning the
beta-band (8–20 Hz), which was abnormally strong in all PD
monkeys (respective peak power frequencies for the four sub-
jects were 10, 11, 12, and 15 Hz; Figure S3A; Stein and Bar-
Gad, 2013). This suppression of LFP oscillations was observed
in all animals and, notably, in all parts of the cortico-basal
ganglia-thalamic loop (although it did not reach significance
level, p < 0.05, in GPe when comparing averaged power spectra;
Figures 2B and 2C, p < 0.05,Wilcoxon rank sum test on band po-
wer 8–20 Hz). In agreement with the behavioral effects, beta sup-
pression could be obtained using both low- and high-frequency
SCS paradigms with approximate equal efficacy (average
LFP power spectra ON/OFF stimulation for all animals and fre-
quencies are presented in Figure 2B).
Next, we examined the effects of SCS on single unit activity.
Overall, approximately one-third of the neurons recorded in the
lesioned hemispheres displayed significant changes in firing
rates associated with SCS. In contrast to the effect on LFP and
motor behavior, SCS modulation of neuronal firing rate differed
markedly according to the stimulation frequency (Figure 3A;
see also Figure S3C). Whereas stimulation at low frequencies
(4–20 Hz) caused mostly excitatory neuronal responses, inhibi-
tory firing modulation predominated during high-frequency stim-
ulation (80–300 Hz; Pearson correlation between the ratio of
inhibitory/excitatory responses and stimulation frequency was:
primary motor cortex, r = 0.96, p < 0.01; putamen, r = 0.74,Neuron 84, 716–722, November 19, 2014 ª2014 Elsevier Inc. 717
Figure 1. Spinal Cord Stimulation Alleviates Motor Symptoms in Parkinsonian Primates
(A) Average effect on general motility in response to SCS. Each color line represents one recorded animal over all trials.
(B–D) Average recovery of locomotion: bout distance, bout frequency and duration, respectively (colors represent the four different subjects and asterisks denote
significant group differences).
(E) Reduction in bradykinesia reflected by the preferential recovery of faster movement components in locomotion.
(F) Average improvements in PD score in all testing sessions divided by symptom category (mean and SEM shown).
(G) Example of functional motor improvement from a state of severe parkinsonism enabling an animal to retrieve food reward using skilled reaching and grasping
movements.
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Spinal Cord Stimulation Alleviates Parkinsonismp < 0.05; ventral posterolateral thalamic nuclei, r = 0.94, p < 0.01;
ventrolateral thalamic nuclei, r = 0.76, p < 0.05; subthalamic nu-
cleus, r = 0.92, p < 0.01; GPe and globus pallidus pars interna not
significant, Figure 3B).
Consistent with the LFP oscillatory activity, we observed a
large fraction of neurons with beta oscillatory firing in the OFF
period (Figure 3C) that was partially suppressed during the
SCS ON period (Figures 3D, 3E, and S2). In total, 152 of 273
(56%) neurons from the lesioned hemispheres displayed signif-
icant beta range (8–16 Hz) rhythmic firing patterns during the
OFF periods (p < 0.01, as compared to spectra computed
from equivalent random spike trains). Of these 152 neurons,
39 (26%) significantly decreased their beta rhythmicity during
the SCS ON period. The change in beta power for all units
with significant rhythmic activity in the beta range is summa-
rized in Figure 3F.
Taken altogether, these data suggest that SCS-inducedmotor
deficit relief is primarily associated with the disruption of syn-
chronized oscillatory activity rather than with specific changes
in firing rate. However, because cortico-basal ganglia activity
is known to be strongly influenced by behavioral state, neuro-
physiologic changes could also result, to some extent, from sec-718 Neuron 84, 716–722, November 19, 2014 ª2014 Elsevier Inc.ondary changes in animal motor behavior. Therefore, to further
clarify how SCS induces neurophysiologic changes that may
cause symptomatic relief, we compared the neuronal activity
patterns from the lesioned hemisphere during SCS, in the two
hemilesioned animals, to either the patterns of the intact hemi-
sphere or to the lesioned hemisphere following L-DOPA treat-
ment (subcutaneous 15 mg/kg with benserazide 6.25 mg/kg).
Recordings were split into 4 s epochs that were classified as
either active or inactive states based on automatically quantified
motor activity. To facilitate comparisons between states, two
separate indices were constructed. First, two vectors were
created summarizing the mean differences (parkinsonian versus
intact state) and (parkinsonian versus L-DOPA-treated state),
respectively, in two multidimensional parameter spaces—spec-
tral LFP power and firing rate per structure. Each recorded epoch
could then be represented as a point in the parameter spaces
and be quantitatively compared to the intact or L-DOPA treated
state by geometrical projection onto these vectors. Using this
metric, it was evident that SCS treatment caused a shift toward
healthy brain activity patterns resembling the effect of L-DOPA
treatment. This effect was observed only for the analysis of
LFP spectral power and not for neuronal firing rates (Figure S3B).
Figure 2. Spinal Cord Stimulation Alters Neuronal Activity Patterns in Basal Ganglia Circuits
(A) Example of parallel changes in LFP power in multiple structures of the cortico-basal ganglia-thalamic loop. For each brain structure, right depicts pooled LFP
spectrograms (brain slice figures reproduced with permission from Palazzi and Bordier, The Marmoset Brain in Stereotaxic Coordinates, Springer Science+-
Business Media). Note the immediate reduction of low-frequency oscillations (beta band) in response to SCS (red bar, stimulation frequency: 4 Hz; color codes
denote decibels above pink noise background for LFPs).
(B) Average LFP spectra for all recording sessions normalized to pink noise showing a significant SCS-induced reduction in LFP beta-power in all structures
except GPe. Shaded area denotes 95% CI with 100 bootstraps.
(C) Changes in normalized firing rates of individual neurons were diverse but, on average, they decreased in response to SCS in globus pallidus pars interna and
ventrolateral thalamic nuclei.
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fect due to an active or inactive behavioral state because a two-
way ANOVA, used to estimate the relative effect size of SCS
compared to that of behavioral state, showed that only 2.9%
and 0.8% of the total variance (eta-squared; using the metric
for the intact and L-DOPA treated state, respectively) could be
attributed to behavioral state change, whereas the effect of
SCS treatment explained 13.4% and 10.8%of the total variance.
Consequently, the main effect shared by both SCS and L-
DOPA treatment appears to be the suppression of the excessive
neuronal population synchronization associated with the parkin-
sonian state. Although it is not clear how coordinated low-fre-
quency activity patterns arise in PD, it is possible that an altered
functional coupling between the circuit elements of the cortico-basal ganglia-thalamic loop may be a key underlying factor (Wil-
liams et al., 2002). To test this idea, we computed the coherence
of the LFP signals between pairs of different neural structures
as an indirect measure of their functional connectivity. In the 6-
OHDA lesioned dopamine-depleted hemispheres, we found
strong coherence between pairs of structures, but only in the
parkinsonian low-frequency range (8–15 Hz) (Figure 4A, black
traces). Importantly, like the L-DOPA treatment, SCS reduced
the beta coherence (Figure 4A red trace), leading to a significant
functional decoupling between the different structures. This sug-
gests that SCS brings the functional connectivity of the cortico-
basal ganglia-thalamic circuit closer to the normal state of the
intact brain. Indeed, this decoupling of parkinsonian LFP oscilla-
tions in the beta band was observed between all the recordedNeuron 84, 716–722, November 19, 2014 ª2014 Elsevier Inc. 719
Figure 3. Spinal Cord Stimulation Alters the Firing Rate and Rhythmicity of Neuronal Units in Basal Ganglia Circuits
(A) Standardized neuronal firing rate response to different SCS frequencies in multiple structures of the basal ganglia circuits (neurons rank ordered according to
responses).
(B) The fraction of inhibitory responses increased with higher SCS frequencies.
(C) Autocorrelograms of two single units in primary motor cortex exemplifying beta-range rhythmic firing pattern in a parkinsonian animal (SCS OFF).
(D) Autocorrelograms of the same two units showing that the rhythmic spiking is effectively interrupted by SCS.
(E) The respective power spectra OFF/ON (black/red) for the units shown in (C) and (D). Note the peak (arrow) in the beta-range during the OFF period, which
disappears during the ON period.
(F) Changes in power of rhythmic beta-firing plotted for all 183 units that presented significant beta oscillations either in the OFF or ON period. Colored circles
represent the units with significant suppression in beta power during the ON period. Black line denotes equal power in ON and OFF conditions, thus units located
to the right of the line display beta suppression.
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Spinal Cord Stimulation Alleviates Parkinsonismstructures and was found to be very similar following L-DOPA
and SCS (Figure 4B).
To further explore the underlying mechanisms whereby SCS
alters network activity, we recorded neural activity while deliv-
ering single or pairs of SCS pulses. These recordings showed
that primary somatosensory pathways (ventral posterolateral
thalamic nuclei and primary somatosensory cortex) are activated
early by SCS and that a disruption of beta oscillations through a
phase-reset mechanism appears to cause the observed wide-
spread desynchronization in the beta band (Figure S4; Fuentes
et al., 2010; Popovych and Tass, 2012).
DISCUSSION
In conclusion, we observed that SCS caused clear clinical
improvements in a primate model of PD (comparable to, for
example, the reported long-term reduction in UPDRS III score
by DBS, 28%, Follett et al., 2010) and, in particular, for motor
signs known to be difficult to treat with DBS. These include def-
icits in posture, gait, and speed of locomotion (Krack et al.,720 Neuron 84, 716–722, November 19, 2014 ª2014 Elsevier Inc.2003). Concurrent multisite neuronal recordings showed that
significant behavioral improvements induced by SCS were
strongly associated with desynchronization of neuronal activity
within the cortico-basal ganglia circuitry and reduction in beta-
frequency coherence between structure pairs. We therefore pro-
pose that SCS should be further tested in clinical studies aimed
at measuring its long-term efficacy as a less invasive, long-term
therapy for patients with PD.
EXPERIMENTAL PROCEDURES
Five adult male common marmosets (Callithrix jacchus) 300–550 g were used
in the study. The animals were housed in pairs in cages (1.03 1.03 2.3 m) in a
vivarium with a natural light cycle (12/12 hr) and outdoor temperature. All ani-
mal procedures were carried out according to approved protocols by AASDAP
Ethics Committee and strictly in accordance with the NIH Guide for the Care
and Use of Laboratory Animals (NIH Publications no. 80-23). This project
was approved by SISBIO/Brazilian Institute of Environment and Natural Re-
sources under no. 20795-2.
Neurotoxic lesions were inflicted with the animals under deep anesthesia.
Two microliters of 6-OHDA solution (4 mg/ml, 0.05% ascorbic acid, saline)
were injected into the medial forebrain bundle in (AP/ML/DV): 6.5/1.2/6.0;
Figure 4. Spinal Cord Stimulation and
L-DOPA Treatment Suppresses Multistruc-
ture LFP Coherence
(A) Example of LFP coherence spectra from one of
the hemilesioned animals (black trace) showing
coherent oscillations restricted to the beta-band in
the parkinsonian condition (arrows) that are sup-
pressed by SCS (red trace; bold line and shaded
area denote median and interquartile range,
stimulation artifacts around 20 and 40 Hz have
been removed).
(B) Connectivity diagram representing the pooled
LFP coherence in the 8–15 Hz range in relation to
the30–40Hzbandbetweenall pairs of electrodes in
the different structures (values represent averages
from all five recordings in the two hemilesioned
animals; all changes in beta-to-gamma coherence
for SCS ON/OFF are significant p < 0.05, Wilcoxon
rank sum test). Note that the excessive beta-band
coherence, represented by the warm colors in the
parkinsonian state, is effectively reduced by SCS in
the same way as for L-DOPA treatment.
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Spinal Cord Stimulation Alleviates Parkinsonism6.5/1.2/7.0; 6.5/2.2/6.5; 6.5/2.2/7.5; and 6.5/3.2/8.0 (Annett et al., 1992). AP
coordinates were scaled according to the dimensions of the skull of each
animal (Stephan et al., 1980).
The following parkinsonian symptoms were assessed in the transparent
acrylic box: episodes of freezing, uncoordinated gait, difficulty using finemotor
skills, episodes of bradykinesia, hypokinesia, balance impairment, and
posture. The assessment methods were based on previously described pro-
cedures (Bankiewicz et al., 2001; Campos-Romo et al., 2009; Fahn and Elton,
1987; Verhave et al., 2009) and are thoroughly described in the Supplemental
Experimental Procedures. Automatic motion tracking was performed using
custom developed software in MATLAB.
LFPs and action potentials were recorded using a multi-channel recording
system (Plexon).
Analyses of recorded signals were performed according to previously
described methods (Fuentes et al., 2009; Halje et al., 2012).
The position of the recording electrode positions and the extent of dopami-
nergic lesions were verified through quantitative tyrosine hydroxylase staining
in all animals.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, and two movies and can be found with this article online at
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AUTHOR CONTRIBUTIONS
M.S, H.S, P.H., R.F, P.P, and M.A.L.N. designed the experiments; M.S, H.S,
R.F., and P.P performed the surgeries; M.S. conducted experiments; M.S.
and M.F. performed immunohistochemistry; M.S., P.H., U.R., P.P., R.F., and
M.A.L.N. analyzed the data, andM.S., P.H, U.R, P.P., R.F., andM.A.L.N. wrote
the paper.
ACKNOWLEDGMENTS
We thank Tobias Palme´r for developing the video tracking software used for
automatic quantification of locomotor behavior, Jim Meloy and Gary Lehew
for building recording electrodes, Ivani Brys for statistical discussion, Carlos
Eduardo Idalino for support with data analysis, Pedro Calvacanti for support
in IHC, and Marcelo Carvalho for technical support. This research was sup-
ported by The Michael J. Fox Foundation for Parkinson’s Research; FINEP
01.06.1092.00; INCEMAQ—Program of National Institutes of Science and
Technology of CNPq/MCT; the Swedish Research Council (325-2011-6441);Swedish Society forMedical Research; theOlle Engkvist, Parkinson Research,
Crafoord, A˚ke Wiberg, Magnus Bergvall, Kockska and Segerfalk Foundation;
Hja¨rnfonden, and an NIH Transformative award (R01-NS073125-03).
Accepted: August 28, 2014
Published: October 30, 2014
REFERENCES
Agari, T., and Date, I. (2012). Spinal cord stimulation for the treatment of
abnormal posture and gait disorder in patients with Parkinson’s disease.
Neurol. Med. Chir. (Tokyo) 52, 470–474.
Annett, L.E., Rogers, D.C., Hernandez, T.D., and Dunnett, S.B. (1992).
Behavioural analysis of unilateral monoamine depletion in the marmoset.
Brain 115 (Pt 3), 825–856.
Bankiewicz, K.S., Sanchez-Pernaute, R., Oiwa, Y., Kohutnicka, M., Cummins,
A., and Eberling, J. (2001). Preclinical models of Parkinson’s disease. In
Current Protocols in Neuroscience (John Wiley & Sons), pp. 9.4.1–9.4.32.
Benabid, A.L., Pollak, P., Louveau, A., Henry, S., and de Rougemont, J. (1987).
Combined (thalamotomy and stimulation) stereotactic surgery of the VIM
thalamic nucleus for bilateral Parkinson disease. Appl. Neurophysiol. 50,
344–346.
Campos-Romo, A., Ojeda-Flores, R., Moreno-Brisen˜o, P., and Fernandez-
Ruiz, J. (2009). Quantitative evaluation of MPTP-treated nonhuman parkinso-
nian primates in the HALLWAY task. J. Neurosci. Methods 177, 361–368.
Fahn, S., and Elton, R.L. (1987). Unified Parkinson’s disease rating scale.
Recent Dev. Park. Dis. 2, 153–163.
Fe´nelon, G., Goujon, C., Gurruchaga, J.-M., Cesaro, P., Jarraya, B., Palfi, S.,
and Lefaucheur, J.-P. (2012). Spinal cord stimulation for chronic pain improved
motor function in a patient with Parkinson’s disease. Parkinsonism Relat.
Disord. 18, 213–214.
Follett, K.A., Weaver, F.M., Stern, M., Hur, K., Harris, C.L., Luo, P., Marks,
W.J., Jr., Rothlind, J., Sagher, O., Moy, C., et al.; CSP 468 Study Group
(2010). Pallidal versus subthalamic deep-brain stimulation for Parkinson’s dis-
ease. N. Engl. J. Med. 362, 2077–2091.
Fuentes, R., Petersson, P., Siesser, W.B., Caron, M.G., and Nicolelis, M.A.L.
(2009). Spinal cord stimulation restores locomotion in animal models of
Parkinson’s disease. Science 323, 1578–1582.
Fuentes, R., Petersson, P., and Nicolelis, M.A. (2010). Restoration of locomo-
tive function in Parkinson’s disease by spinal cord stimulation: mechanistic
approach. Eur. J. Neurosci. 32, 1100–1108.Neuron 84, 716–722, November 19, 2014 ª2014 Elsevier Inc. 721
Neuron
Spinal Cord Stimulation Alleviates ParkinsonismHalje, P., Tamte`, M., Richter, U., Mohammed, M., Cenci, M.A., and Petersson,
P. (2012). Levodopa-induced dyskinesia is strongly associated with resonant
cortical oscillations. J. Neurosci. 32, 16541–16551.
Hassan, S., Amer, S., Alwaki, A., and Elborno, A. (2013). A patient with
Parkinson’s disease benefits from spinal cord stimulation. J. Clin. Neurosci.
20, 1155–1156.
Krack, P., Batir, A., Van Blercom, N., Chabardes, S., Fraix, V., Ardouin, C.,
Koudsie, A., Limousin, P.D., Benazzouz, A., LeBas, J.F., et al. (2003). Five-
year follow-up of bilateral stimulation of the subthalamic nucleus in advanced
Parkinson’s disease. N. Engl. J. Med. 349, 1925–1934.
Landi, A., Trezza, A., Pirillo, D., Vimercati, A., Antonini, A., and Sganzerla, E.P.
(2012). Spinal cord stimulation for the treatment of sensory symptoms in
advanced Parkinson’s disease. Neuromodulation 16, 276–279.
Mitchell, I.J., Hughes, N., Carroll, C.B., and Brotchie, J.M. (1995). Reversal of
parkinsonian symptoms by intrastriatal and systemic manipulations of excit-
atory amino acid and dopamine transmission in the bilateral 6-OHDA lesioned
marmoset. Behav. Pharmacol. 6, 492–507.
Morgante, L., Morgante, F., Moro, E., Epifanio, A., Girlanda, P., Ragonese, P.,
Antonini, A., Barone, P., Bonuccelli, U., Contarino, M.F., et al. (2007). How
many parkinsonian patients are suitable candidates for deep brain stimulation
of subthalamic nucleus? Results of a questionnaire. Parkinsonism Relat.
Disord. 13, 528–531.722 Neuron 84, 716–722, November 19, 2014 ª2014 Elsevier Inc.Nicolelis, M.A., Fuentes, R., Petersson, P., Thevathasan, W., and Brown, P.
(2010). Spinal cord stimulation failed to relieve akinesia or restore locomotion
in Parkinson disease. Neurology 75, 1484, author reply 1484–1485.
Popovych, O.V., and Tass, P.A. (2012). Desynchronizing electrical and sensory
coordinated reset neuromodulation. Front. Hum. Neurosci. 6, 58.
Stein, E., and Bar-Gad, I. (2013). b oscillations in the cortico-basal ganglia loop
during parkinsonism. Exp. Neurol. 245, 52–59.
Stephan, H., Baron, G., and Schwerdtfeger, W.K. (1980). The Brain of the
Common Marmoset (Callithrix jacchus) : A Stereotaxic Atlas. (New York:
Springer).
Thevathasan, W., Mazzone, P., Jha, A., Djamshidian, A., Dileone, M., Di
Lazzaro, V., and Brown, P. (2010). Spinal cord stimulation failed to relieve aki-
nesia or restore locomotion in Parkinson disease. Neurology 74, 1325–1327.
Verhave, P.S., Vanwersch, R.A., van Helden, H.P.M., Smit, A.B., and
Philippens, I.H.C.H.M. (2009). Two new test methods to quantify motor deficits
in amarmosetmodel for Parkinson’s disease. Behav. Brain Res. 200, 214–219.
Williams, D., Tijssen, M., Van Bruggen, G., Bosch, A., Insola, A., Di Lazzaro, V.,
Mazzone, P., Oliviero, A., Quartarone, A., Speelman, H., and Brown, P. (2002).
Dopamine-dependent changes in the functional connectivity between basal
ganglia and cerebral cortex in humans. Brain 125, 1558–1569.
